Rainbird Technologies names Klick Health exclusive North American life sciences partner

Rainbird Technologies and Klick Health have entered an exclusive partnership aimed at revolutionising healthcare product commercialisation through Rainbird's advanced Decision Intelligence platform. This collaboration leverages Rainbird's proven platform, utilised by the UK's National Health Service and various regulated sectors globally, in conjunction with Klick Health's industry-leading knowledge and tools. 

As the exclusive Rainbird service partner in life sciences, Klick Health will integrate its expertise to enhance patient data analysis, optimise clinical trial designs, and navigate regulatory complexities. The Rainbird AI platform adopts a "top-down" decision intelligence approach, starting with policies and procedures and then reasoning to approval decisions, providing transparency and explainability critical in highly regulated environments.

Focused on eliminating organisational bottlenecks and maximising opportunities for biopharmaceutical organisations, Klick Health aims to usher in a new era of data-driven pharma commercialisation with Rainbird's intelligent automation decision intelligence. Unlike traditional "bottom-up" machine learning systems, Rainbird's approach is particularly valuable for new brands, companies, or situations where past approvals are lacking or outdated. 

The platform's ability to simulate human-like reasoning without compromising accuracy, speed, or scalability sets it apart. James Duez, Rainbird Co-Founder and CEO, emphasised the advantage their technology provides in ensuring compliance with regulations and delivering transparent solutions. Klick Health's EVP of Data Science, Alfred Whitehead, expressed confidence that combining Rainbird's decision intelligence with language models from platforms like OpenAI, Microsoft, AWS, and Google will yield optimal results for their clients.

The partnership reinforces Klick Health's leadership in the AI and machine learning space, following its groundbreaking research on a voice-based AI model for detecting Type 2 diabetes and the recent launch of the first ChatGPT plugin for life sciences companies.